NDC 70518-4495-00 - Metronidazole
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70518-4495
- Requested NDC
- 70518-4495-00
- Package NDCs from labels
- 70518-4495-0, 70518-4495-00
- Manufacturer
- REMEDYREPACK INC.
- Effective date
- 2026-09-14
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Metronidazole - REMEDYREPACK INC. | REMEDYREPACK INC. | 2026-09-14 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70518-4495-0 | Metronidazole | 70 g in 1 TUBE, WITH APPLICATOR | GEL | 70 | 1 | |
| 70518-4495-0 | Metronidazole | 1 in 1 CARTON | GEL | 1 | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Metronidazole | METRONIDAZOLE | REMEDYREPACK INC. | 1a28dce0-07af-401a-a6ac-1c2ee559c668 | 2026-01-19 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| PYLERA | BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE | H2-Pharma, LLC | c50626a2-5969-490b-a88a-a4ee45e79615 | 2026-01-16 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| metronidazole | METRONIDAZOLE | Preferred Pharmaceuticals Inc. | ab695a3e-1721-491a-97a2-c3f617a8d9fc | 2026-01-14 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| Metronidazole | METRONIDAZOLE | GLENMARK PHARMACEUTICALS INC., USA | 6736c100-a7fe-44ea-8579-5537537ff9b8 | 2026-01-09 | Warnings, Adverse reactions | 142046 140QMO216E |
| METRONIDAZOLE | METRONIDAZOLE | Direct_Rx | 90a5acb3-f8cc-1e82-e053-2995a90a4e97 | 2026-01-08 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| Metronidazole | METRONIDAZOLE | American Health Packaging | c90da73c-e48e-411a-bd75-0b107f1141cc | 2026-01-08 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| Metronidazole | METRONIDAZOLE | Solaris Pharma Corporation | 94a83daa-6e34-419d-849a-6f18d3b8c586 | 2026-01-07 | Warnings, Adverse reactions | ANDA213648 73473-303 142046 a3efeca5-5c4b-432b-9537-ea2e1e67c17c 94a83daa-6e34-419d-849a-6f18d3b8c586 140QMO216E |
| metronidazole | METRONIDAZOLE | Northwind Health Company, LLC | 06bd4afb-4a45-294c-e063-6394a90a7ab1 | 2026-01-01 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| Metronidazole | METRONIDAZOLE | Northwind Health Company, LLC | f2f55405-7f21-3ccc-e053-2a95a90a195a | 2026-01-01 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| Metronidazole | METRONIDAZOLE | Northwind Health Company, LLC | f7e5dacd-0bc4-4ac4-e053-6394a90a457a | 2026-01-01 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| Metronidazole | METRONIDAZOLE | Proficient Rx LP | a56c2842-8ad4-4396-8eb6-cbcd1629fcb1 | 2026-01-01 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| Metronidazole | METRONIDAZOLE | Redpharm Drug | 300b51d0-8fca-24ef-e063-6294a90ad2b9 | 2025-12-23 | Adverse reactions | 140QMO216E |
| Metronidazole | METRONIDAZOLE | Redpharm Drug | 32523df9-8c47-200f-e063-6294a90ac890 | 2025-12-18 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| Metronidazole | METRONIDAZOLE | Chartwell RX, LLC | 40509b3c-b725-400c-abe5-d6d5714d405d | 2025-12-17 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| Metronidazole | METRONIDAZOLE | A-S Medication Solutions | 60ad086d-6f54-4134-b608-53a6ff571ff8 | 2025-12-03 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| Metronidazole | METRONIDAZOLE | A-S Medication Solutions | 2a5af710-dbf7-41c1-9b3a-35e69b3fa4ab | 2025-12-03 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| Metronidazole | METRONIDAZOLE | A-S Medication Solutions | 9a18debb-3bb8-4b23-949b-aaa0f3b62191 | 2025-12-03 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| Vandazole | METRONIDAZOLE | Upsher-smith Laboratories, LLC | 27d71471-8f89-4a1e-8c55-020a58961454 | 2025-12-02 | Warnings, Adverse reactions | 142046 140QMO216E |
| Metronidazole | METRONIDAZOLE | Civica, Inc. | 902ab25b-d493-495a-884e-96b080e9f72d | 2025-11-21 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
| Bismuth subcitrate potassium, Metronidazole, Tetracycline hydrochloride | BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE | Ingenus Pharmaceuticals, LLC | 4c7f024d-ba26-43cf-a36f-597e2168cd9f | 2025-11-11 | Boxed warning, Warnings, Adverse reactions | 140QMO216E |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.